A microRNA that regulates inflammation shows promise as a treatment for inflammatory diseases such as asthma and cancer, according to research published in Cell Reports.
The microRNA, known as miR-223, is highly expressed in blood cells that cause inflammation (neutrophils). When they’re working correctly, those blood cells help protect the human body against infections, but sometimes they damage host tissue instead of microbes, causing chronic inflammation and disease.
To uncover the link between miR-223 and inflammation, a Purdue University research team created a zebrafish totally deficient of miR-223. Then they cut off a small chunk of its fin.
“The inflammation was really robust,” said Qing Deng, a professor of biological sciences at Purdue and corresponding author of the paper. “Neutrophils accumulated at the wound and they just kept coming. This is consistent with the literature, but we wanted to understand why.”
Extensive gene expression analysis led them to pathway NF-kB, a protein complex found in nearly all animal cell types that regulates inflammation and cell proliferation. Heightened activation of this pathway is the cause of increased inflammation, although it’s limited to the deeper, or basal, layer of the epithelium. This means any therapeutics would need to reach the basal layer to work.
The same pathway plays an important role in human bronchial epithelial cells, which are critical in the development of asthma, according to the study. MiR-223 suppresses the pathway, which means supplementing it to epithelial cells could help control inflammatory disease.
“We don’t have human trials yet, but we think it’s promising,” Deng said. “Instead of using steroids to drive away the immune cells, maybe this microRNA could be given.”
Learn more: MicroRNA could help treat cancer and asthma
The Latest on: MicroRNA
via Google News
The Latest on: MicroRNA
- Study provides a reliable early prognostic biomarker for COVID-19 severityon July 6, 2021 at 4:16 pm
In a retrospective, multi-centre cohort study conducted by researchers from Nanjing University, Huazhong University of Science and Technology, Jinling Hospital and the Second Hospital of Nanjing, a ...
- SARS-CoV-2 encoded miRNA is a biomarker for stratification of severe patientson July 6, 2021 at 9:24 am
In a retrospective, multi-center cohort study, a microRNA-like small RNA encoded by SARS-CoV-2 was identified in the serum of COVID-19 patients. This can be developed as a non-invasive biomarker for ...
- Arctic Vision and HKU enter glaucoma therapy development dealon July 5, 2021 at 7:32 am
Chinese company Arctic Vision has entered a new research partnership with the University of Hong Kong’s (HKU) Ophthalmology department to discover and develop new neuroprotective treatments for ...
- Uncovering the genetic mechanism behind Rett syndromeon July 2, 2021 at 2:53 pm
Researchers found that the main gene that causes Rett syndrome, MeCP2, controls the differentiation pattern of neural stem cells through the microRNA miR-199a. Dysfunction in MeCP2 or miR-199a cause ...
- COVID-19 Virus Produces microRNA That Can Have Impacts on Infected Cellson June 23, 2021 at 1:02 am
New research published in the Journal of Cellular and Molecular Medicine indicates that SARS-CoV-2, the virus that causes COVID-19, produces microRNAs that can have impacts on infected cells. MicroRNA ...
- MicroRNA Market Size to Grow at a CAGR of 16.8% During the Forecast Period 2021-2026on June 22, 2021 at 5:46 am
Jun 22, 2021 (The Expresswire) -- The MicroRNA Market size was estimated at $32.38 billion in 2020, projected to grow at a CAGR of 16.8% during the forecast period 2021-2026. MicroRNA, also known ...
- MicroRNA Market Projected to be Resilient During 2030on June 16, 2021 at 3:31 am
The global microRNA market is predicted to expand at a whopping growth rate over the 2020 – 2030 forecast period. This is mainly attributed to emergence of microRNA tools for disease-related ...
via Bing News